Researchers at Texas A&M are pairing a widely used ingredient with advanced medical technology to develop new treatments for ...

Nobel laureate Jennifer Doudna, PhD; Matthew Porteus, MD, PhD, and Rodolphe Barrangou, PhD—offer their views on the commercial potential and challenges of genome editing following a rollercoaster 2025 ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (“Scribe”), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective ...

One of the most inherent risks is the risk of damaging healthy genes. This rather brutal issue is step one of risk management. It also means large sequences of amino acids that must be checked, ...